Is Hidradenitis Suppurativa An Autoimmune Disease?
If you have hidradenitis suppurativa (HS), you may have heard people call it an autoimmune disease. But research from the past few years shows that's not quite accurate. Experts now say HS is better understood as an autoinflammatory condition.
Autoimmune diseases happen when your body's immune system attacks healthy tissue by mistake, usually involving specific antibodies. But with autoinflammatory conditions, your body's built-in immune defenses overreact without any clear reason, causing inflammation, pain, and swelling.
A 2023 study looked at a part of the immune system called the AIM2 inflammasome and found that it plays a key role in triggering HS. This supports the idea that HS is caused by an overactive immune response, not by the body attacking itself like it does in autoimmune diseases.
In 2024, researchers placed HS in a group of conditions called autoinflammatory keratinization diseases. These involve skin inflammation and blocked hair follicles, not the kind of immune system behavior seen in classic autoimmune illnesses.
More recent research from 2025 focused on a specific immune protein called IL-17, which drives inflammation in HS. Treatments that block IL-17 are showing promise, which aligns with the idea that HS is rooted in inflammation, not autoimmunity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Cigna Enhances myCigna Platform With AI Assistant, Personalized Care, Cost Tools
The Cigna Group (NYSE:CI) is one of billionaire Leon Cooperman's top stock picks with huge upside potential. On June 12, Cigna Healthcare, the health benefits arm of The Cigna Group (NYSE:CI), revealed new digital capabilities designed to enhance the consumer experience during routine health insurance interactions. The myCigna member interface will be used to gradually roll out the new technologies, which include a virtual assistant driven by AI, personalized provider matching, real-time cost tracking, intelligent claim submission, and assistance with plan selection. The AI-powered virtual assistant offers tailored responses to inquiries concerning benefits, claims, and available care options, according to Cigna Healthcare. According to preliminary findings, more than 80% of clients who had access to the virtual assistant found it useful. Additionally, in order to help customers with complicated health needs have their administrative problems resolved more quickly, The Cigna Group (NYSE:CI) is investing in centralized agent teams and increasing access to dedicated My Personal Champion advocates. The Cigna Group (NYSE:CI) specializes in providing insurance and associated services in the United States, such as pharmaceutical benefits, home delivery pharmacy, and specialty pharmacy distribution. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Photo App Could Spot Anemia in Seconds
Artificial intelligence (AI) plays an increasingly prominent role in the workplace, and health researchers are exploring its potential to improve the diagnosis and treatment of diseases. In this context, the company Sanguina Inc., based in the US, has developed an app called Ruby Health, designed to help detect anemia using just a photo of a patient's fingernails. Currently available for Android and iOS devices in the US, the app's effectiveness was detailed in a study published by Sanguina's research team in the journal PNAS . The study and the companion tool grew out of an academic project launched in 2015 by Wilbur Lam, Erika Tyburski, and Rob Mannino. 'The development was rigorous. The idea came from the fact that, for decades, we have known that patients with anemia have paleness in some parts of the body, such as their fingernails, so we thought about the possibility of a noninvasive method, such as an app, to measure this paleness without having to draw blood,' said Lam, a researcher at Emory University School of Medicine in Atlanta, Georgia. Since its launch in 2021, Ruby Health has registered 1.4 million users in the US upload fingernail photos to estimate hemoglobin (Hgb) levels and may manually enter the lab results. Researchers then compare estimated Hgb with blood-test values to gauge accuracy. Among individuals with Hgb between 7 g/dL and 17 g/dL, the mean absolute error was ±0.72 g/dL. Using an Hgb cutoff of 12.5 g/dL to define anemia, the application demonstrated a sensitivity of 89% and a specificity of 93%. For Lam, this tool is promising. 'Based on the values entered, when calibrated, our app works similarly to blood-based methods. With 'homemade' methods, there is always the concern that they do not translate to what is tested in the lab, but we demonstrated the usability of the platform by replicating data in a closed clinical environment and in the real world,' he said. The platform's personal records feature allows for the personalization of treatment tips for patients, and geolocation data helps map cases for the application of public policies and the allocation of treatment resources. However, Ruby Health has limitations: It does not detect very low Hgb levels (< 7 g/dL) and cannot identify the type of anemia the patient has, which is crucial for determining treatment. 'Anemia is not a disease itself but a condition secondary to many illnesses,' said Helena Zerlotti Wolf Grotto, MD, professor of Clinical Pathology at Universidade Estadual de Campinas, Campinas, Brazil, laboratory-hematology consultant, and member of the Brazilian Association of Hematology. 'To determine the cause of anemia, it is necessary to perform tests, evaluate the patient's history and perform a physical examination, since treatment involves comprehensive care,' she said. The gold standard for diagnosing anemia remains the complete blood count, which identifies the type of anemia and its possible causes. 'Screening tests like this app could be useful in remote or resource‐limited areas,' Grotto added. However, in the United States, the app was more widely adopted in areas with higher average incomes, better access to primary care, and a higher proportion of Black residents. In Brazil, Grotto sees limited benefit in urban centers with broad access to laboratory tests, as the public health system already provides robust anemia testing. She is also concerned about accuracy in Black patients, since AI tools often lack adequate training to identify darker skin tones, which could hinder the app's functionality among Brazilians or other mixed-race populations. However, Lam stated that the app's algorithm has been tested on different skin tones and that nails have a lower amount of melanin, which minimizes the variability in skin color from one person to another. Although not 100% accurate, the app can be used to indicate the possibility of a person having anemia in certain cases, according to experts. The developers themselves have stated that it is not suitable for emergency clinical decision-making. 'The market is full of innovations, but we must remain critical before assuming they will solve every problem,' Grotto said.
Yahoo
an hour ago
- Yahoo
Novo Nordisk terminates collaboration with Hims & Hers Health
Novo Nordisk (NVO) said in a statement on Monday that it would halt its collaboration with Hims & Hers Health (HIMS) and that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy. The two companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy weight loss drug through a bundled offering on the telehealth company's platform. Shares of Hims & Hers have fallen about 18% in pre-market trading following the news. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
